The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update
- Author:
Lan HUANG
1
;
Guohua LIANG
;
Qingyuan ZHANG
;
Wenhui ZHAO
Author Information
- Publication Type:Review Article
- From:Journal of Breast Cancer 2020;23(2):129-140
- CountryRepublic of Korea
- Language:English
- Abstract: As a standard treatment, endocrine therapy has dramatically enhanced the prognosis of patients with estrogen receptor (ER)-positive breast cancer, which accounts for nearly 70% of all breast cancers. Antiestrogen drugs such as tamoxifen and aromatase inhibitors are the standard treatment options for ERα-positive breast cancer. However, acquired antiestrogen resistance is still the leading cause of disease recurrence and progression. Evidence has shown that long noncoding RNAs (lncRNAs) play an essential role in the development of antiestrogen resistance in ER-positive breast cancer and can serve as biomarkers or potential therapeutic targets. This review highlights the role of lncRNAs in the development of antiestrogen resistance in breast cancer.
